インドにおけるトップ10製薬企業null...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 12
1.2 List of Figures 14
2 Introduction 16
2.1 Report Scope 16
2.2 Upcoming Related Reports 18
2.3 Recently Published Reports 18
2.4 GlobalData’s Benchmarking Methodology 19
3 India’s Pharmaceutical Industry Dynamics 20
3.1 Overview 20
3.2 Intellectual Property Rights in India 20
3.3 Quality Manufacturing Facilities Create an Ideal Environment for Pharmaceuticals to Thrive 22
3.4 Inter-Firm Competition Enables Capabilities Development 24
3.5 Government Policies and Initiatives Drive Demand 24
3.6 Increased ANDA Filings by Indian Drug Companies 25
3.7 Cost Effect of GDUFA on Indian Drug Companies 30
3.8 A Budding Biosimilars Market 31
3.8.1 Gradual Transition from a Semi-Regulated to a Regulated Market 31
3.8.2 Marketed Biosimilars in India 32
4 Company Analysis 34
4.1 Sun Pharmaceuticals: The Benchmark Leader 34
4.1.1 Business Overview 34
4.1.2 SWOT Analysis 35
4.2 Wockhardt 39
4.2.1 Business Overview 39
4.2.2 SWOT Analysis 40
4.3 Cipla 43
4.3.1 Business Overview 43
4.3.2 SWOT Analysis 44
4.4 Ranbaxy 47
4.4.1 Business Overview 47
4.4.2 SWOT Analysis 48
4.5 Lupin Pharmaceuticals 52
4.5.1 Business Overview 52
4.5.2 SWOT Analysis 53
4.6 Zydus Cadila 56
4.6.1 Business Overview 56
4.6.2 SWOT Analysis 57
4.7 Glenmark 60
4.7.1 Business Overview 60
4.7.2 SWOT Analysis 61
4.8 Torrent Pharmaceuticals 65
4.8.1 Business Overview 65
4.8.2 SWOT Analysis 66
4.9 Dr. Reddy’s 70
4.9.1 Business Overview 70
4.9.2 SWOT Analysis 71
4.10 Aurobindo Pharmaceuticals 75
4.10.1 Business Overview 75
4.10.2 SWOT Analysis 76
5 GlobalData’s Benchmark Rankings 78
5.1 Sun Pharmaceuticals: India’s Leading Pharmaceutical Company 78
6 Financial Management 80
6.1 Competitive Framework 80
6.2 Overview 80
6.3 Financial Management: Heat Map 82
6.4 Financial Metrics 83
6.4.1 Revenue Leaders 83
6.4.2 Revenue Laggards 85
6.4.3 Revenue Growth Leaders 86
6.4.4 Revenue Growth Laggards 88
6.4.5 Operating Income Leaders 90
6.4.6 Operating Income Laggards 91
6.4.7 Operating Income YTY Growth Leaders 93
6.4.8 Operating Income YTY Growth Laggards 94
6.4.9 Operating Margin Leaders 95
6.4.10 Operating Margin Laggards 97
7 Expense Management 99
7.1 Competitive Framework 99
7.2 Overview 100
7.3 Expense Management: Heat Map 103
7.4 Expense Metrics 104
7.4.1 SG&A Spending Leaders 104
7.4.2 SG&A Spending Laggards 105
7.4.3 SG&A Expenditures as a Percentage of Revenue Leaders 106
7.4.4 SG&A Expenditures as a Percentage of Revenue Laggards 108
7.4.5 SG&A Spending YTY Change Leaders 110
7.4.6 SG&A YTY Spending Change Laggards 111
7.4.7 Operating Expenses as a Percentage of Revenue Leaders 113
7.4.8 Operating Expenses Laggards 114
8 Capital Management 116
8.1 Competitive Framework 116
8.2 Overview 116
8.3 Competitive Framework: Heat Map 118
8.4 Capital Management Metrics 119
8.4.1 Debt Ratio Leaders 119
8.4.2 Debt Ratio Laggards 120
8.4.3 Cash Ratio Leaders 121
8.4.4 Cash Ratio Laggards 124
8.4.5 Quick Ratio Leaders 125
8.4.6 Quick Ratio Laggards 126
8.4.7 ROI Leaders 127
8.4.8 ROI Laggards 128
9 Resource Management 130
9.1 Competitive Framework 130
9.2 Overview 130
9.3 Resource Management: Heat Map 133
9.4 Financial Metrics 134
9.4.1 Revenue per Employee Leaders 134
9.4.2 Revenue per Employee Laggards 135
9.4.3 Expenditure per Employee Leaders 137
9.4.4 Expenditure per Employee Laggards 138
10 Geographical Segmentation 140
10.1 India 140
10.2 Europe, Middle East, and Africa 142
10.3 North America 144
10.4 Rest of World 146
11 Strategic Outlook 147
11.1 Current Growth in the Indian Pharmaceutical Industry Expected to Continue 147
11.2 Increased Focus on R&D 148
11.3 Government’s Pricing Revision Will Further Reduce Margins 148
11.4 Stiff Competition from Multinationals May Stymie Development of Smaller Domestic Players 149
11.5 Growing Pressures on Indian Patent Laws Could Challenge Domestic Companies 150
12 Appendix 151
12.1 Bibliography 151
12.2 Abbreviations 153
12.3 Research Methodology 157
12.3.1 Coverage 157
12.3.2 Secondary Research 158
12.3.3 Expert Panel Validation 158
12.4 About the Authors 159
12.4.1 Analyst 159
12.4.2 Director of Healthcare Industry Dynamics 159
12.4.3 Global Head of Healthcare Research and Consulting 160
12.5 About the Industry Dynamics Team 160
12.6 About GlobalData 160
12.7 Disclosure Information 161
12.8 Disclaimer 161